José Ramón Paño
@joserrapa.bsky.social
MD, ID, AMS, SALUD, HCUZ, IISA, AI, ES, EU, ESCMID, EIS, CMI-CMIComms, SEIMC
Reposted by José Ramón Paño
I think a lot of non-US based researchers have little interest in traveling to the US (can’t blame them). Wish getting to ESCMID on VA funds wasn’t so hard
July 17, 2025 at 12:06 AM
I think a lot of non-US based researchers have little interest in traveling to the US (can’t blame them). Wish getting to ESCMID on VA funds wasn’t so hard
"The four major tetM-carrying lineages circulating since 2020 together account for 83% of tetM-carrying isolates".
(...)
"Of the four major lineages, two carry variants in penA (encoding penicillin-binding protein 2 [PBP2], the main target of ceftriaxone) that increase ceftriaxone resistance"
(...)
"Of the four major lineages, two carry variants in penA (encoding penicillin-binding protein 2 [PBP2], the main target of ceftriaxone) that increase ceftriaxone resistance"
July 10, 2025 at 2:44 AM
"The four major tetM-carrying lineages circulating since 2020 together account for 83% of tetM-carrying isolates".
(...)
"Of the four major lineages, two carry variants in penA (encoding penicillin-binding protein 2 [PBP2], the main target of ceftriaxone) that increase ceftriaxone resistance"
(...)
"Of the four major lineages, two carry variants in penA (encoding penicillin-binding protein 2 [PBP2], the main target of ceftriaxone) that increase ceftriaxone resistance"
